BioNTech
phase first in human study of | BioNTech
Company
Deck Type
Sector
Industry
Deck date
March 2022
Slide
19 of 37
Related slides by other companies
Nuvalent
Investor Presentation
January 2024
the path to patient impact ams program status first approved and pivotal data study for phase ongoing with registrational intent for patients with execute on global registrational strategies additional discovery research programs ongoing product study for alk demonstrated clinical proof of concept in phase with mission bringing new best in class medicines to patients with cancer planned development in both and alk planned phase initiation in for her i | Nuvalent
Arbutus Biopharma
Investor Presentation
November 2023
small molecule oral inhibitor for | Arbutus Biopharma
23andMe
Investor Day
January 2022
phase study of me in patients with locally advanced or metastatic solid malignancies | 23andMe
ATAI
Investor Presentation
October 2023
is well tolerated with a favorable safety profile demonstrated across clinical studies in patients dosed including up to the highest single dose of and daily dose of tid in two placebo controlled phase studies in over patients was dosed up to tid for six months rates of headache and gastrointestinal issues were comparable to placebo representing a differentiated profile from certain competitor programs in development for does not induce sedation which is distinct from agonists initial phase a study confirmed safety and tolerability profile in schizophrenia patients including on top of standard of care with no evidence of safety concerns on any of the safety measures labs physical exam vitals aes | ATAI
Other recent decks by BioNTech
See all presentations (12 decks)
Investor Presentation
August 2022
Results
August 2022
Investor Day
June 2022
Investor Day
February 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights